This innovative approach could revolutionize glioblastoma treatment, potentially improving survival rates and reducing tumor recurrence. However, the technology is still in early-stage research and has only been tested in animal models. Human trials are necessary to confirm its safety and efficacy. If successful, this could provide a significant breakthrough for patients suffering from this challenging form of brain cancer, which currently has a five-year survival rate of just 7%.